Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kymera Therapeutics Inc
(NQ:
KYMR
)
48.54
-0.93 (-1.88%)
Streaming Delayed Price
Updated: 3:51 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Kymera Therapeutics Inc
< Previous
1
2
3
4
Next >
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474
March 10, 2022
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...
Via
Benzinga
Why Is It Moving? Looking Into Why Kymera Therapeutics's Stock is Trading Higher Today
April 14, 2021
Kymera Therapeutics's Stock Price And Volume Action Kymera Therapeutics (NASDAQ:
Via
Benzinga
48 Biggest Movers From Yesterday
January 14, 2022
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58...
Via
Benzinga
Kymera Discloses New Development Cancer Program
December 16, 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to...
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Where Kymera Therapeutics Stands With Analysts
September 30, 2021
Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More
July 11, 2021
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to...
Via
Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...
Via
Benzinga
Kymera Prices $223M Equity Offering At $47/Share
July 01, 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount...
Via
Benzinga
58 Biggest Movers From Yesterday
July 02, 2021
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
31 Stocks Moving in Wednesday's Pre-Market Session
June 30, 2021
Gainers Bridgeline Digital, Inc. (NASDAQ: BLIN) shares rose 83% to $6.20 in pre-market trading. Bridgeline Digital shares jumped over 36% on Tuesday on above-average volume....
Via
Benzinga
72 Biggest Movers From Yesterday
July 01, 2021
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
June 29, 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to an...
Via
Benzinga
51 Stocks Moving In Wednesday's Mid-Day Session
June 30, 2021
Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
60 Biggest Movers From Yesterday
June 29, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...
Via
Benzinga
Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers
June 28, 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy...
Via
Benzinga
Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity
June 21, 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...
Via
Benzinga
Mid-Afternoon Market Update: Dow Gains Over 100 Points; Bed Bath & Beyond Shares Plummet
April 14, 2021
Toward the end of trading Wednesday, the Dow traded up 0.33% to 33,787.64 while the NASDAQ fell 0.62% to 13,908.97. The S&P also fell, dropping 0.22% to 4,132.40. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 14, 2021
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 18.37% to $31.44 during Wednesday's regular session. As of 12:31 EST, Nurix Therapeutics's stock is...
Via
Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
48 Biggest Movers From Yesterday
April 15, 2021
Gainers Alkami Technology, Inc. (NASDAQ: ALKT) shares surged 43.3% to settle at $43.00 on Wednesday after the company priced its IPO at $30 per share. Coinbase Global, Inc. (...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
30 Stocks Moving In Wednesday's Mid-Day Session
April 14, 2021
Gainers Discovery, Inc. (NASDAQ: DISCB) shares climbed 37.3% to $102.99. Grupo Televisa, S.A.B. (NYSE: TV) shares climbed 22.4% to $12.39 after the company reached an agreement...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021
April 14, 2021
Upgrades For Cardlytics Inc (NASDAQ:CDLX), Craig-Hallum upgraded the previous rating of Hold to Buy. For the fourth quarter, Cardlytics had an EPS of $0.05, compared to...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.